This Week’s Biopharma News: New Approvals, Appeals, and AI
June 2, 2026
Datroway and Hepcludex secure notable FDA approvals, while Outlook wins its bevacizumab appeal, BioMarin reports phase 3 VOXZOGO data, and BMS partners with Anthropic
6 min read
False
Advertisement
Industry News
This Week’s CGT News: Base Editing Takes Aim at Cholesterol
June 1, 2026
Verve reports phase 1 data for one-time PCSK9 base editing; plus: neuroprotective gene therapy, non-viral DNA delivery, tumour-activated CAR-T, and in vivo CAR-M
3 min read
This Week’s Biopharma News: ADCs, Biosimilars, and Microbiome Moves
May 26, 2026
Merck’s TROP2 ADC delivers a phase III win in endometrial cancer, as new golimumab biosimilars and an oral microbiome therapy move forward
7 min read
This Week’s CGT News: Duchenne Gene Therapy Hits Pivotal Mark
May 25, 2026
REGENXBIO reports phase III AAV data in Duchenne; plus: adenoviral immunotherapy, preconditioning-free CAR-T, in vivo immune programming, and DNA-guided CRISPR
6 min read
This Week’s Biopharma News: FDA Commissioner Steps Down
May 19, 2026
Marty Makary’s resignation puts the agency under acting leadership, while BMS and Hengrui unveil a multibillion-dollar pipeline deal and GSK lines up a chronic hepatitis B launch in China.
3 min read
This Week’s CGT News: Novo’s Parkinson’s Pivot
May 18, 2026
Novo Nordisk’s Parkinson’s cell therapy finds a new home at Cellular Intelligence, while base editing, prime editing, and large-insertion genome writing push forward
6 min read
This Week’s Biopharma News: Amgen Deepens US Manufacturing Push
May 12, 2026
The company adds $300 million to its Puerto Rico biologics site as Pfizer reports Phase 3 myeloma data, J&J advances a dual-pathway IBD antibody, and BioNTech streamlines production
6 min read
This Week’s CGT News: CAR-T Breaks New Ground in Alzheimer’s
May 11, 2026
First CAR-T approach for Alzheimer’s reduces amyloid plaques in mice, while cell and gene therapies advance across blood cancers, retinal disease, amyloidosis, and FSHD
6 min read
This Week’s Biopharma News: EU Clears First Pertuzumab Biosimilar
May 5, 2026
Plus: NICE backs rozanolixizumab for uncontrolled gMG, Genexine reports SOX2 degrader data, and BeOne secures option on Huahui trispecific antibody
4 min read
This Week’s CGT News: CRISPR Hits Phase 3 Milestone
May 4, 2026
Intellia’s one-time HAE therapy delivers strong results as Cabaletta strikes CAR-T manufacturing deal
6 min read
